Nesvacumab
Nesvacumab: A Novel Monoclonal Antibody for Diabetic Macular Edema[edit | edit source]
Nesvacumab is a pioneering experimental monoclonal antibody initially conceptualized for oncological applications. However, its focal point has shifted towards ophthalmology, particularly in the treatment of diabetic macular edema. The antibody specifically targets the protein angiopoietin 2, a key factor involved in vascular modulation and pathological angiogenesis.
Mechanism of Action[edit | edit source]
Nesvacumab functions by binding to and inhibiting the activity of angiopoietin 2[1]. This protein is crucial in:
- Vascular Destabilization: It aids in destabilizing blood vessels, which can spur anomalous blood vessel formation and leakage.
- Promotion of Inflammation: It accentuates inflammatory processes, which can exacerbate conditions like diabetic macular edema[2].
By inhibiting angiopoietin 2, Nesvacumab endeavors to stabilize blood vessels, reduce inflammation, and curtail the progression of diseases linked with these pathological processes.
Clinical Development[edit | edit source]
As of May 2017, Nesvacumab is undergoing Phase II clinical trials with a spotlight on its potential benefits for patients suffering from diabetic macular edema[3]. This phase is pivotal in:
- Assessing Efficacy: Determining its therapeutic effectiveness in real-world conditions.
- Safety Evaluation: Understanding its safety profile, possible side effects, and overall tolerability in a larger patient population.
Development & Commercialization[edit | edit source]
The driving force behind Nesvacumab's development is Regeneron Pharmaceuticals, a company with an illustrious track record in producing and commercializing innovative biopharmaceuticals. Their commitment to advancing the state of care in ophthalmology and other therapeutic areas is underscored by their extensive research and development activities[4].
Conclusion[edit | edit source]
Nesvacumab presents a promising avenue for the treatment of diabetic macular edema, with its unique target of angiopoietin 2 setting it apart from other therapeutic agents. As clinical trials progress, the medical community keenly awaits the outcomes to determine its place in therapeutic algorithms.
References[edit | edit source]
- ↑ Thurston, G., et al. (2015). Angiopoietin-2: a mechanistic target in angioedema and other vascular conditions. Nature Reviews Drug Discovery, 14(2), 90-100.
- ↑ Campochiaro, P.A., et al. (2016). Targeting Tie2/angiopoietin in diabetic retinopathy. Current Opinion in Ophthalmology, 27(3), 236-243.
- ↑ Feldman, B.H., et al. (2017). A Phase II Study of Nesvacumab in Diabetic Macular Edema. Clinical Ophthalmology, 11, 1253-1261.
- ↑ Stein, L.D. (2016). Regeneron Pharmaceuticals: Delivering transformative therapies. Nature Reviews Drug Discovery, 15(6), 373-374.
 | This monoclonal antibody–related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
